Clinical Trials Logo

Renal Cell Adenocarcinoma clinical trials

View clinical trials related to Renal Cell Adenocarcinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01497821 Completed - Clinical trials for Renal Cell Carcinoma

AMG 172 First in Human Study in Patients With Kidney Cancer

Start date: January 2012
Phase: Phase 1
Study type: Interventional

This is the first-in-human (Phase I) study of AMG 172, an antibody drug conjugate (ADC), in subjects with kidney cancer [Clear Cell Renal Cell Carcinoma (ccRCC)] who have relapsed or who have refractory disease following at least two prior therapies. The purpose of the study is to evaluate safety and pharmacokinetics (PK) of AMG 172, and also evaluate the objective response rate in patients with ccRCC receiving AMG 172. The study will be conducted in two Parts: Part 1 will explore doses of AMG 172 given every two weeks and every three weeks to determine the safety, tolerability and pharmacokinetics to establish a maximum tolerated dose (MTD), and Part 2 (dose expansion) will examine safety, tolerability, PK and overall response rate in subjects treated at the MTD established in Part 1 for either every two week or every three week dosing.